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Abstract
Background and objectives: Estrogen receptor signaling and cyclin D1 have a major
role in tumor cell proliferation in breast cancer. Desmoid tumors are rare neoplasms
that may respond to endocrine treatment. The present study aimed to investigate the
expression levels and the clinical relevance of estrogen receptor beta (ERβ) and cyclin
D1 in desmoid tumors.
Methods: This study consists of 83 patients with a surgically treated desmoid tumor.
ERβ and cyclin D1 expression was examined by immunohistochemistry in tissue
microarrays. Cyclin A and Ki67 were studied in our previous work.
Results: Median ERβ expression was 10.8%. ERβ expression correlated with
expression of the proliferation antigens Ki67 (rp = 0.35, P = 0.003), cyclin D1
(rp = 0.34, P = 0.004), and cyclin A (rp = 0.34, P = 0.004). ERβ immunoexpression
showed a trend towards predictive impact for recurrence as a continuous variable.
Further explorative analysis indicated that very high ERβ expression was related to
high risk of relapse (hazard ratio [HR] 2.6; P = 0.02).
Median cyclin D1 expression was 15.6%. High cyclin D1 expression was associated
with high Ki67 and cyclin A expression. Cyclin D1 was not associated with time to
recurrence.
Conclusions: ERβ and cyclin D1 immunopositivity correlated with high proliferation
in desmoid tumors. High ERβ expression might be predictive for postoperative
recurrence.
K E YWORD S
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1 | INTRODUCTION
Desmoid tumors (desmoid fibromatosis) are locally aggressive
tumors with elevated incidence during pregnancy and at postpartum
suggesting a hormonal influence.1 Pregnancy‐associated tumors
typically arise in the abdominal wall while other desmoids can occur
in different parts of the body in musculoaponeurotic tissues. Tumors
show pathognomonic mutation either in the APC gene or in the
β‐catenin gene CTNNB1, which causes a disruption in the canonical
Wnt/β‐catenin pathway. Active surveillance is an alternative for
indolent desmoid tumors without critical location. When therapy is
indicated, surgery, radiotherapy, and systemic therapy including
endocrine therapy are utilized.
The function of the nuclear receptor family member estrogen
receptor beta (ERβ) varies in different tissues, cancer types, and
stages. The role of ER signaling has long remained elusive in desmoid
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tumors. Early reports on desmoid tumors showed no estrogen
receptor expression. The discovery of the second main estrogen
receptor isoform, ERβ, subsequently led to positive ERβ findings in
desmoid tumors.2 The vast majority of desmoid tumors express ERβ
but not estrogen receptor alpha (ERα).3 Selective estrogen receptor
modulators such as tamoxifen act on both receptor subtypes.4
However, in contrast to breast cancer, estrogen receptor expression
was not predictive for response to endocrine therapy in desmoid
tumors in a small retrospective study.5
Cyclin D1 is a cell cycle promoter frequently overexpressed in
neoplastic cells. Accumulated β‐catenin may induce cyclin D1
transcription as a coregulator in desmoid tumors.6 Cyclin D1
activates cyclin‐dependent kinases (Cdk) 4 and 6, which function as
a complex in transition from G1 checkpoint to the S phase by
phosphorylating the retinoblastoma tumor suppressor protein. ERα
upregulates cyclin D1 in breast cancer and thus inhibition of ERα
with endocrine agents results in cell cycle arrest.7 In hormone
refractory breast cancer and other cancers, various proliferative
pathways may induce cyclin D1 and Cdk 4/6, such as PI3K.8 Highly
specific Cdk inhibitors target Cdk 4 and 6 and act synergistically with
hormonal therapy in breast cancer.9,10 An overall survival benefit
was reported in a randomized trial with the first‐in‐class Cdk 4/6
inhibitor palbociclib combined with fulvestrant in locoregionally
advanced or metastatic hormone receptor‐positive HER2‐negative
breast cancer.11 Overall survival results from trials with the Cdk 4/6
inhibitors ribociclib and abemaciclib are pending, but both prolong
time to progression similarly to palbociclib.12,13
Little information is available about the expression and tumor
biological roles of ERβ and cyclin D1 in desmoid tumors. Our study
aimed to investigate the immunohistochemical expression of cyclin
D1 and ERβ and their association with clinicopathological features
and prediction of recurrence in desmoid tumors.
2 | MATERIALS AND METHODS
2.1 | Patients
Desmoid tumor patients treated at Helsinki University Hospital
between 1987 and 2011 were included. A sarcoma expert
pathologist (MR) reviewed the histopathologic diagnosis and con-
firmed it for all the included 90 patients. Clinical data were collected
from the patient records. The Ethics Committee of Helsinki
University Hospital (270/13/03/00/2011) and the Ministry of
Welfare and Health approved this retrospective study. The study
followed the Declaration of Helsinki.
2.2 | Tissue arrays and immunohistochemistry
The tissue microarray (TMA) and immunohistochemical procedures
are described in our previous work.14 Briefly, the TMA was
constructed of formalin‐fixed paraffin‐embedded desmoid tumor
tissue specimen. The TMA blocks were cut into 4‐μm slices. After
antigen retrieval in Tris‐EDTA buffer (pH 9), the immunostaining
were generated with mouse monoclonal cyclin D1 antibody (Ventana
Medical Systems, Tucson, AZ; prediluted in Ventana diluent) and ERβ
antibody (Ventana Medical Systems, Tucson, AZ; dilution 1:100).
The TMA sections were digitalized with Pannoramic 250 scanner
(2DHistech, Budapest, Hungary). Representative areas were anno-
tated and evaluated in Pannoramic Viewer and NuclearQuant
(3DHistech, Budapest, Hungary) software modules, respectively.
Immunostaining was scored as continuous percentages of positive
nuclear staining. A minimum of 100 cells for ERβ and 300 cells for
cyclin D1 were regarded as evaluable. If over 500 cells were detected
in a cyclin D1 specimen, this score was chosen. If multiple scores with
over 500 cells were recognized for one patient, the highest score was
accepted. Expression of ERβ and cyclin D1 was scored with an image
analysis software, as previously prescribed for the proliferation
antigens Ki67 and cyclin A.14 Cut‐offs for positive expression was set
at 1% for ERβ and both at 5% and at 10% for cyclin D1 (Figure 1).
Ki67 and cyclin A expression were examined in our previous study.14
2.3 | Statistical analysis
Statistical analysis was performed with SPSS 25 software (SPSS,
Chicago, IL). Pearson’s correlation coefficient was used with
continuous variables and the student t test for dichotomous variables
for testing the association of ERβ and cyclin D1 and other variables.
Two alternative cut‐offs for ERβ was used in these models, 1% and
28.7% (at 70th percentile). The association between cyclin D1
expression and proliferation was tested separately in ERβ‐positive
and ‐negative groups in a mixed general ANOVA model (Table S1). P
value was considered significant when <0.05. All P values were two‐
tailed. Cox regression model and Kaplan‐Meier estimates were used
to analyze the association between cyclin D1 or ERβ expression and
time to recurrence (TTR). Since there was an association between
cyclin D1 and use of postoperative radiotherapy, TTR analyses were
stratified for radiotherapy. In addition to analyses with cyclin D1 or
ERβ as continuous values, exploratory TTR analyses with cut‐offs
ranging from the 10% to the 90% deciles were also performed.
Kaplan‐Meier plots of TTR with cyclin D1 and ERβ divided into
tertiles were generated to detect any nonlinear association.
3 | RESULTS
Cyclin D1 and ERβ expression were evaluable in 77 and 83 of 90
patients, respectively. Due to missing and unsuccessful immunostain-
ing or too low a cell number, 13 and 7 patients were excluded from
the analyses. The median follow‐up period was 11 years (range from
0.1 to 29 years). Clinical features and associations with cyclin D1 and
ERβ expression are listed in Table 1.
3.1 | Expression of cyclin D1 and ERβ
Cyclin D1 expression varied from 0.7 to 90.7% (mean
20.1%, median 15.6%, and interquartile range 21.0%). The
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distribution was highly skewed with predominantly low
values (Figure S1). With a 5% cut‐off, cyclin D1 was expressed
in 63 of 77 patients (82%) and with a 10% cut‐off in 64%. Nuclear
ERβ expression varied from 0% to 74% (mean 19.3%, median
10.8%, and interquartile range 31.1%). Like for cyclin D1, the
distribution was skewed towards low expression values (Figure
S2). With a 1% cut‐off, ERβ was positive in 68 of 83
patients (82%).
3.2 | Associations between clinical variables,
proliferation, and immunohistochemical expression of
cyclin D1 and ERβ
Cyclin D1 expression correlated positively with ERβ (rp = 0.34,
P = 0.004), Ki67 (rp = 0.40, P = 0.001), and cyclin A (rp = 0.34,
P = 0.004). Cyclin D1 expression was significantly higher in males
(P = 0.047), and on patients receiving postoperative radiotherapy
(P = 0.006; Tables 1 and 2). In addition to cyclin D1, ERβ
expression correlated with Ki67 (rp = 0.35, P = 0.003) and cyclin
A (rp = 0.40, P < 0.001). Neither cyclin D1 nor ERβ expression was
associated with tumor size or location, patient age, sex, surgical
margin, pregnancy or familial adenomatous polyposis (FAP). ERβ
expression was not associated with sex or postoperative radio-
therapy.
Separate analyses of the association between cyclin D1 and
proliferation were done in ERβ‐negative and ‐positive groups to
detect any modifying effect of ER expression of this association. The
correlation between cyclin D1 expression and proliferation was
similar in both ERβ‐negative and ‐positive groups with no sign of
statistically significant interaction (Table S1).
3.3 | Prediction of recurrence
Cyclin D1 overexpression was not significantly associated with TTR
neither as a continuous variable nor when divided into two groups by
different cut‐offs and stratified by postoperative radiotherapy (Table
3; Figure S3). As a continuous variable, ERβ expression showed a
trend towards an increased risk of recurrence (hazard ratio [HR]
1.02, 95% CI = 1.0‐1.04; P = 0.06). Dividing the patient material into
two groups with varying cut‐offs, on the other hand, revealed a
significant association between high ERβ expression and higher risk
of recurrence at the 70th and 80th deciles (cut‐offs 28.9% and 38.4%,
and P values 0.02 and 0.04, respectively, Table 3). Figure 2 illustrates
the Kaplan‐Meier curves of ERβ expression and TTR at the optimal
cut‐off of 28.9%.
4 | DISCUSSION
In the present study, we demonstrate that ERβ expression correlates
with high cyclin D1, Ki67, and cyclin A expression in desmoid tumors.
To the best of our knowledge, the association between proliferation
and ERβ expression has not been described before in desmoid
tumors. ERβ or cyclin D1 exhibited no predictive impact on
recurrence after surgery in the main analysis. However, explorative
analysis using different cut‐off values demonstrated a significant
negative association between very high expression of ERβ and TTR.
Due to their exploratory nature, the significant association between
high ERβ and a short TTR has to be confirmed in an independent
patient cohort. The biological rationale for an association between
high ERβ and high risk of recurrence may be the positive correlation
between ERβ and proliferation found in the present study. Our
F IGURE 1 Immunohistochemical
expression of cyclin D1 and estrogen
receptor beta (ERβ) in desmoid tumors: (A)
low ERβ < 1%, (B) high ERβ ≥ 1%, (C) low
cyclin D1 < 5%, and (D) high cyclin D1 ≥ 5%
[Color figure can be viewed at
wileyonlinelibrary.com]
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previous observation was that high proliferation is associated with a
higher recurrence risk.14 We found no indication of a linear
association between cyclin D1 expression and TTR, although cyclin
D1 expression was also associated with higher proliferation rate
measured by the expression of Ki67 and cyclin A.
Despite the documented hormonal dependence of desmoid
tumors, expression of ERα has been negative in the vast majority
of studies.3,15 An earlier report suggested that ERα antibody cross‐
linkage with ERβ may have elicited a few positive ERα findings.16
Many previous studies have, however, reported that ERβ is
expressed in desmoid tumors. ERβ overexpression has varied from
7% to 100% with cut‐offs from any positivity to 10%.3,5,16-18 The first
ERβ expression studies with a 10% cut‐off reported only 9% (7/80)
and 7% (2/27) positivity.3,18 With the lower 1% cut‐off in the present
study ERβ was positive in 82% (68/83) of patients with a median
expression value of 10.8%. A previous study with the same 1% cut‐off
reported a 90% positivity rate (53/59).5 Other investigators found a
100% ERβ expression in 27 and 40 desmoid tumor patients when the
cut‐off was set at 5% or detectable staining, respectively.16,17 Besides
different cut‐offs, different antibody clones, immunohistochemistry
methods, scoring methods, and patient population selection may
explain the somewhat divergent results. The majority of studies, like
the present one, show that ERβ is expressed in a large proportion of
desmoid tumors. The proportion of positive cells is relatively low.
Cyclin D1 was expressed in the majority of desmoid tumors in our
study but, like ERβ, at a relatively low rate with a medium value of
15.6%. A previous study reported cyclin D1 positivity in 44% (30/69)
of patients with a 10% cut‐off.19 Two previous studies using a cut‐off
of 5% showed cyclin D1 positivity in 71% (27/38) in sporadic and
64% (11/17) in FAP‐associated desmoid tumors.6,15 Although some-
what higher (82% and 64% with cut‐offs at 5% and 10%, respectively)
than in previous studies, our results and the previous studies indicate
TABLE 2 Correlations of estrogen receptor β (ERβ) and cyclin D1
Cyclin D1 ERβ
Factors Median % (IQR) P value Correlation coefficient P value Correlation coefficient
ERβ 10.8 (31.1) 0.004 0.34
Cyclin D1 15.6 (21.0) 0.004 0.34
Ki67 0.001 0.40 0.003 0.35
Cyclin A 0.004 0.34 0.001 0.40
Abbreviations: ERβ, estrogen receptor beta; IQR, interquartile range.
TABLE 3 Cyclin D1 and ERβ expression classified from 10th to 90th percentiles in Cox univariate analysis
Cyclin D1a ERβ
Cut‐off % Cut‐off % HR (95% CI) P value Cut‐off % HR (95% CI) P value
10 2.9 0.8 (0.2‐3.6) 0.8 0.4 2.9 (0.4‐21.3) 0.3
20 5.2 1.4 (0.4‐4.7) 0.6 1.6 1.2 (0.4‐3.7) 0.7
30 7.8 1.9 (0.6‐5.9) 0.2 2.4 1.3 (0.5‐3.3) 0.6
40 11.5 1.9 (0.7‐5.0) 0.2 4.5 1.7 (0.7‐4.0) 0.3
50 15.6 1.7 (0.7‐4.1) 0.3 10.8 1.6 (0.7‐3.7) 0.3
60 18.5 0.7 (0.2‐1.7) 0.4 17.8 1.8 (0.8‐4.0) 0.2
70 22.8 0.6 (0.2‐1.7) 0.3 28.7 2.6 (1.2‐6.0) 0.02
80 29.6 0.5 (0.1‐1.9) 0.3 38.4 2.5 (1.1‐5.9) 0.04
90 46.5 1.1 (0.3‐5.1) 0.8 54.8 2.1 (0.7‐6.3) 0.2
Abbreviations: CI, confidence interval; ERβ, estrogen receptor beta; HR, hazard ratio.
aCyclin D1 analysis was stratified by postoperative radiotherapy.
F IGURE 2 Kaplan‐Meier analysis of ERβ expression and time to
recurrence using 28.7% cut‐off in 81 patients with resected desmoid
tumor. ERβ, Estrogen receptor beta
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that cyclin D1 is expressed in a large proportion of desmoid tumors,
but in most cases at a relatively low level. Cyclin D1 expression in
desmoid tumors may be related to the connection between β‐catenin
expression and cyclin D1.6 The cyclin D1 gene CCND1 is a
transcriptional target of the Wnt/β‐catenin signaling pathway and
the effect may be reinforced by the amplification of the CCND1 gene
reported to be frequent in desmoid tumors.6
In the present study, cyclin D1 expression was associated with
increased proliferation measured by the expression of Ki67 (rp = 0.4)
and cyclin A (rp = 0.3). A previous study by Saito et al
6 did not find any
significant association between cyclin D1 and Ki67 expression in
desmoid tumors, however, a significant association between cyclin
D1 expression and the proliferation antigen PCNA was reported. The
low number of patients (n = 38) might be the reason for the
discrepant associations between cyclin D1 and the two proliferation
markers but the final cause remains unclear. It is to be pointed out,
however, that the correlation between cyclin D1 and proliferation,
despite being significant, was not strong in the present study. This
indicates that other factors in addition to cyclin D1 are responsible
for activation of the cell cycle in this disease.
In breast cancer, there is a close relationship between ER
expression and the effect on cyclin D1 expression on cell cycle
activation and prognosis.7 To test whether this is the case also in
desmoid tumors, we tested the association between cyclin D1 and
proliferation separately in groups defined by ERβ expression. We
found no signs of modification of ERβ expression on the association
between cyclin D1 and increased proliferation in the present study.
This indicates that the interplay between estrogen, estrogen
receptor, cyclin D1, and cell cycle activation is different in desmoid
tumors and breast cancer.
The function of ERβ is tissue‐specific, and in breast cancer, in
contrast to ERα signaling, ERβ signaling suppresses proliferation;
whereas ERβ has been described to have a role in tissue regeneration
after muscle injury, indicating a different role in mesenchymal
tissues.4,20 To our knowledge, this is the first study in desmoid
tumors to show a positive correlation between proliferation markers
and ERβ expression. The association between ERβ expression found
in the present study as well as its tentative predictive effect indicates
that ERβ expression may play a role in the pathophysiology of
desmoid tumors. The association may be a part of the signaling
pathway linking endocrine factors to the growth of the desmoid
tumor.
The advantages and the limitations of the patient material, TMA
technique, and immunohistochemistry are discussed in our earlier
work.14 Briefly, strengths of the study include a histological re‐
evaluation of all diagnoses and long and complete follow‐up; a
potential weakness is the use of TMA instead of whole sections.
5 | CONCLUSIONS
In conclusion, in the current study, we showed that both ERβ and
cyclin D1 often are expressed in desmoid tumors, but generally at
a low level. Both markers were associated with increased
proliferation as assessed by cyclin A and Ki67 expression, and
ERβ expression may also be associated with a higher risk of
relapse.
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